Your Search Returned 5 tagged news reports
Funded under DOD's Peer Reviewed Medical Research Program, the amount will be used to assess milatuzumab drug, which is a humanized anti-CD74 antibody, in a subcutaneous formulation for patients with lupus. The clinical tests will be conducted on
P Immunomedics, known for development of monoclonal antibody-based products, has reported efficacy of subcutaneous injections of low-dose Veltuzumab in producing high rates of response in relapsed immune thrombocytopenia (ITP). Veltuzumab, a
As per the agreement, which was originally signed on 11 July 2008, Nycomed is responsible for the development, manufacturing and commercialization of veltuzumab in the subcutaneous formulation to treat all non-cancer indications. The agreement
The patent application 'Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology' will issue as US Patent no...The patent will cover cytokine-antibody complexes made by the DNL technology...
Immunomedics has posted a net income of $744,547 for the second quarter 2010, or $0.01 per diluted share, compared to net income of $854,695, or $0.01 per diluted share, for the comparable period in 2009. Operating income for the second quarter ended